Biweekly report of Beijing stock exchange: 45 companies of Beijing stock exchange expect cash dividends of 1.411 billion yuan

Special research, policies and highlights

As of April 22, 2022, 53 companies of the Beijing stock exchange have announced the annual report of 2021, 8 companies do not pay dividends, and 45 companies have announced the annual equity distribution plan of 2021. Cash dividend is the main dividend method of each company. 45 companies expect the total cash dividend to be 1.411 billion yuan, with an average cash dividend of about 31.36 million yuan per company. Tongli shares and beiteri paid huge cash dividends, with the dividend amounts of 179 million yuan and 170 million yuan respectively, accounting for 48% and 12% of the net profit attributable to the parent company. The driving force and Yongshun biological cash dividends accounted for 85% and 84% of the net profit attributable to the parent company in the current period, and gave back to the shareholders with a high bonus rate. In addition to cash dividends, the companies that have also carried out share conversion include Litong technology, Haixi communication, Suzhou axis Co., Ltd., Chuangyuan instrument, Changfu Co., Ltd., Huawei design, Longzhu technology, Jiaxian Co., Ltd., Guandian defense, Airong software, digital people and Changhong energy; Companies that also send shares include beiteri, Guangzi international and Tonghui information. Eight companies did not pay dividends, including Yingtai biology, Jigang precision, Kaide quartz, Fengguang precision, Sanyuan gene, Kaitian gas, Jilin Carbon Valley and Dezhong automobile. There are two main reasons for not paying dividends: 1) considering the increasing capital demand of the company in the development stage, for example, Kaitian gas disclosed in its annual report that the company will continue to promote the construction of "Yinchuan emergency peak shaving and gas storage facilities" and other projects in 2022, In order to ensure the safety of cash flow, no dividend will be paid in 2021. Fengguang precision said in its annual report that the company will not pay dividends in 2021 because it expects to invest 130 million yuan to build the Shanghai Cooperation plant in 2022.

Market conditions and trading performance

As of April 22, 2022, there were 90 companies listed on the Beijing stock exchange. In the first two weeks, the number of transactions on the Beijing stock exchange totaled 326 million shares, a year-on-year increase of - 1.53%; The turnover was 4.431 billion yuan, a year-on-year increase of - 5.07%; The average transaction price was 13.59 yuan / share, a year-on-year increase of - 3.60%. The top 10 in terms of turnover in the first two weeks were senxuan pharmaceutical, beiteri, Liancheng CNC, Jilin Carbon Valley, Qifeng Seiko, Gaishi food, Changhong energy, digital man, Northland and Yingtai biology; The top 10 in terms of transaction volume are senxuan medicine, Qifeng Seiko, Yingtai biology, liujinnian, Gaishi food, AVIC TEDA, Tonghui information, CSCEC consulting, Tongxin transmission and Northland; The top 10 in turnover rate are Qifeng Seiko, Gaishi food, Tongxin transmission, senxuan medicine, digital man, Haixi communication, AVIC TEDA, Hujiang materials, China design consulting and Dadi electric.

Financing events and tracking

In this period (from April 10 to April 23, the same below), 33 additional plans were added by the Beijing stock exchange, and the total amount of funds raised was 1.227 billion yuan; The total amount of additional issuance was 1.24 billion yuan. In this period, 9 companies were added in the IPO counseling stage of Beijing stock exchange. The companies are: lvheng technology, Hubei Huahua, Beijing Parker international, Chengdu Oukang medicine, Zhejiang Haosheng electronics, Anhui zhongcao flavor, Ningxia Juneng Siasun Robot&Automation Co.Ltd(300024) , Wuxi Haidar and Jiangsu Sanxin.

Risk warning: macroeconomic downside risk; Risk of insufficient liquidity; Large fluctuations in performance and the risk of delisting of the company

- Advertisment -